While mammography is currently the standard of care for breast cancer screening, dense breast tissue can significantly degrade results. Alternatively, infrared spectroscopy analysis of breath offers a highly sensitive method for identifying exhaled volatile organic compounds (VOCs), which may circumvent issues with breast density.
Population-level screening programs aimed at early detection and treatment of breast cancer saves lives. Analyzing breath using infrared spectroscopy offers a highly sensitive, non-invasive, and cost-effective mechanism for identifying exhaled volatile organic chemicals, and it is hypothesized that it may identify differences in the “breathprint” of women with breast cancer relative to those without a breast cancer diagnosis.
Early diagnosis of lung cancer greatly improves the likelihood of survival and remission, but limitations in existing technologies like low-dose computed tomography have prevented the implementation of widespread screening programs. Breath-based solutions that seek disease biomarkers in exhaled volatile organic compound (VOC) profiles…
Currently low-dose computed tomography is used for lung cancer (LC) screening, but is limited by radiation exposure, cost, and a high false detection rate (1,2). An accurate, accessible and affordable screening technology is needed to improve detection of LC in high risk individuals.
Nearly 80% of lung cancer cases are discovered when the disease has already metastasized and survival rates are significantly reduced. Screening is critical to catch the disease in its early, treatable stages. In this study, we consider a screening system based on cavity ring-down spectroscopy (CRDS) analysis of exhaled breath samples. We use machine learning to identify potential biomarkers and develop a classification system for differentiating lung cancer and non-lung cancer individuals.
A Canadian company invented a non-invasive breath test that will detect breast cancer, neurodegenerative diseases and respiratory illnesses.
Blow into a machine to detect cancer. This is the principle of a new tool, developed locally by the medical technology company Breathe BioMedical, which is similar to the breathalyzer. If its effectiveness is proven, it could completely change cancer screenings.
Seeking an accessible diagnostic medium, researchers are rooting through the concoction of compounds in exhaled breath vapor for the metabolic manifestations of disease.
Technologies in development could make cancer screening less of a hassle and more widely available. After his godmother and his business partner’s mother both died of breast cancer, Rubens Fernando Mendrone made a radical change: he quit his job at IBM to become a high-tech innovator and social entrepreneur.